Cencora, Inc. $COR Shares Sold by KBC Group NV

KBC Group NV decreased its position in shares of Cencora, Inc. (NYSE:COR) by 27.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,733 shares of the company’s stock after selling 46,245 shares during the quarter. KBC Group NV’s holdings in Cencora were worth $37,613,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COR. Kemnay Advisory Services Inc. acquired a new position in Cencora during the fourth quarter worth $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in Cencora during the 4th quarter worth about $27,000. Archer Investment Corp boosted its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares during the period. Finally, Motiv8 Investments LLC acquired a new position in Cencora in the 4th quarter valued at about $29,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the purchase, the director owned 4,359 shares in the company, valued at $1,177,932.57. This trade represents a 14.44% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $303.65 on Tuesday. The company has a market capitalization of $59.08 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 1.71 and a beta of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The stock has a 50 day moving average price of $280.85 and a 200 day moving average price of $317.26.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the previous year, the company posted $4.42 EPS. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts predict that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its board has authorized a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Citigroup reduced their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 price target on shares of Cencora in a research note on Friday, May 8th. Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Robert W. Baird reduced their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Wells Fargo & Company lowered their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.